GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aeolus Pharmaceuticals Inc (OTCPK:AOLS) » Definitions » Price-to-Owner-Earnings

AOLS (Aeolus Pharmaceuticals) Price-to-Owner-Earnings : (As of Apr. 28, 2025)


View and export this data going back to 1996. Start your Free Trial

What is Aeolus Pharmaceuticals Price-to-Owner-Earnings?

As of today (2025-04-28), Aeolus Pharmaceuticals's share price is $0.0001. Aeolus Pharmaceuticals does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Aeolus Pharmaceuticals's Price-to-Owner-Earnings or its related term are showing as below:


AOLS's Price-to-Owner-Earnings is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.77
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2025-04-28), Aeolus Pharmaceuticals's share price is $0.0001. Aeolus Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2017 was $-0.04. Therefore, Aeolus Pharmaceuticals's PE Ratio (TTM) for today is At Loss.

As of today (2025-04-28), Aeolus Pharmaceuticals's share price is $0.0001. Aeolus Pharmaceuticals's EPS without NRI for the trailing twelve months (TTM) ended in was $-0.04. Therefore, Aeolus Pharmaceuticals's PE Ratio without NRI for today is At Loss.


Aeolus Pharmaceuticals Price-to-Owner-Earnings Historical Data

The historical data trend for Aeolus Pharmaceuticals's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aeolus Pharmaceuticals Price-to-Owner-Earnings Chart

Aeolus Pharmaceuticals Annual Data
Trend Sep07 Sep08 Sep09 Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aeolus Pharmaceuticals Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Aeolus Pharmaceuticals's Price-to-Owner-Earnings

For the Drug Manufacturers - Specialty & Generic subindustry, Aeolus Pharmaceuticals's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aeolus Pharmaceuticals's Price-to-Owner-Earnings Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aeolus Pharmaceuticals's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Aeolus Pharmaceuticals's Price-to-Owner-Earnings falls into.


;
;

Aeolus Pharmaceuticals Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Aeolus Pharmaceuticals's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.0001/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aeolus Pharmaceuticals  (OTCPK:AOLS) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Aeolus Pharmaceuticals Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Aeolus Pharmaceuticals's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Aeolus Pharmaceuticals Business Description

Traded in Other Exchanges
N/A
Address
26361 Crown Valley Parkway, Suite 150, Mission Viejo, CA, USA, 92691
Aeolus Pharmaceuticals Inc is a Southern California-based biopharmaceutical company. The company is developing a platform of novel compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. Aeolus is developing its lead compound, AEOL-10150, as a treatment for the lung effects of Acute Radiation Syndrome (Lung-ARS). Aeolus also has two pre-clinical development programs: AEOL 11114 and AEOL 20415.
Executives
John L Mcmanus officer: President and CEO C/O AEOLUS PHARMACEUTICALS, INC., 26361 CROWN VALLEY PARKWAY, SUITE 150, MISSION VIEJO CA 92691
Chris A Rallis director C/O TENAX THERAPEUTICS, INC., ONE COPLEY PARKWAY, SUITE 490, MORRISVILLE NC 27560
Amit Kumar director C/O ACACIA RESEARCH CORPORATION, 500 NEWPORT CENTER DRIVE, 7TH FLOOR, NEWPORT BEACH CA 92660
Joseph J Krivulka director C/O DANCE BIOPHARM INC., 150 NORTH HILL DRIVE, SUITE 24, BRISBANE CA 94005
David Cavalier director C/O AEOLUS PHARMACEUTICALS, INC., 23811 INVERNESS PLACE, LAGUNA NIGUEL CA 92677
Michael E Lewis director C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Peter David Suzdak director 1204 MEADOWLARK DRIVE, TOWSON MD 21286
Russell Skibsted officer: Chief Financial Officer 15 TRANQUILITY PLACE, LADERA RANCH CA 92694
Mark Lappe 10 percent owner 11622 EL CAMINO REAL, SUITE 100, SAN DIEGO CA 92130
Bvf Investments Llc 10 percent owner, other: Indirect Beneficial Owner 1 SANSOME ST, 30TH FL, SAN FRANCISCO CA 94104
Biotechnology Value Fund Ii Lp 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Inc/il 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Bvf Partners L P/il 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY ST., 40TH FLOOR, SAN FRANCISCO CA 94104
Biotechnology Value Fund L P 10 percent owner, other: Indirect Beneficial Owner 44 MONTGOMERY STREET, 40TH FL, SAN FRANCISCO CA 94104
Jon Faiz Kayyem 10 percent owner 5964 LA PLACE COURT, CARLSBAD CA 92008

Aeolus Pharmaceuticals Headlines

From GuruFocus